Evidence map›Paper›PMID 35156477›Full record

ArticleTherapeutic advances in respiratory disease

Management of acute exacerbation of chronic obstructive pulmonary disease under a tiered medical system in China.

Xiaojing Liu, Chunlin Du, Fuying Hu, Yunfeng Zhao, Jintao Zhou, Qian Wang, Yutong Mu, Jinchang Lu, Lei Gao, Bo Cui and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Nebulized corticosteroidsFrontiers in pharmacology · 2022
    Review
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaojing LiuDepartment of Respiratory and Critical Care Medicine, Shanghai Institute of Respiratory Disease, Zhongshan Hospital, Fudan University, Shanghai, China Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of Qingdao University, Qingdao, ChinaORCID 0000-0003-4778-8299
Chunlin DuPulmonary and Critical Care Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Fuying HuDepartment of Respiratory Medicine, The First People's Hospital of Tianmen, Tianmen, China.
Yunfeng ZhaoDepartment of Respiratory Disease, Punan Hospital, Shanghai, China.
Jintao ZhouDepartment of Respiratory and Critical Care Medicine, Taicang Hospital, Soochow University, Taicang, China.
Qian WangRespiratory Medicine, Shanghai Jing'an District Zhabei Central Hospital, Shanghai, China.
Yutong MuDepartment of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
Jinchang LuPulmonary and Critical Care Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, China.
Lei GaoDepartment of Respiratory and Critical Care Medicine, Shanghai Institute of Respiratory Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
Bo CuiDepartment of Respiratory and Critical Care Medicine, Shanghai Institute of Respiratory Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan MaDepartment of Respiratory and Critical Care Medicine, Shanghai Institute of Respiratory Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
Tieying SunDepartment of Respiratory and Critical Care Medicine, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.
Feng QianEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, Pharm-X Center, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhihong ChenDepartment of Respiratory and Critical Care Medicine, Shanghai Institute of Respiratory Disease, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Chinese government has promoted the 'tiered medical services' policy in which diseases are classified by severity, mode of onset and difficulty of treatment since 2015 to optimize medical resources. We evaluated the diagnosis and treatment of acute exacerbation (AE) of chronic obstructive pulmonary disease (AECOPD) under the tiered system.

methodsWe conducted a cross-sectional study. COPD characteristics and treatments were compared among hospitals in different tiers. Associations were examined by univariate and multivariable logistic regression analysis. In addition, multivariate logistic regression was performed to identify the possible influencing factors of antibiotics, glucocorticoids and anticoagulant usages.

resultsEligible COPD patients (

conclusionsThe 'tiered medical services' policy in AECOPD management has been unsatisfactory in the past years. Irrational treatment strategies in different hospitals were still found when comparing with international guideline. Further reform of the policy is still needed to optimize the management of AECOPD in China.

Indexed as

Pulmonary Disease, Chronic ObstructiveChinaCross-Sectional StudiesDisease ProgressionGlucocorticoidsHumansSputumGlucocorticoidsacute exacerbationAECOPDtiered medical system

Identifiers

PMID35156477
PMCPMC8848085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.